Cellectis delivered a profitable Q3 2025, supported by significant revenue from its collaboration with AstraZeneca. The company reported a modest net income and positive operating income, reflecting improved financial health.

Cellectis (Cibus) achieved revenue growth in Q4 2024 while significantly reducing net loss compared to the prior year. Operational focus included commercialization progress, expanded strategic collaborations, and cost-cutting measures to extend cash runway.

Cellectis achieved a remarkable revenue increase in Q4 2024, reaching $28.92 million compared to just $0.28 million in the prior year. The company significantly reduced its net loss to $17.13 million from $41.79 million in Q4 2023. Operating losses improved to $21.45 million, supported by a financial gain of $4.77 million. The company ended the quarter with $264 million in cash, ensuring a runway into mid-2027.